KLOW
KLOW blendGLOW with KPVEvidence
Preclinical
Typical vial
80 mg
Route
Subcut
Status
United States
What it is
GLOW with KPV added: four compounds in one vial at 5:1:1:1. The newest and least studied of the common blends.
What is in the vial
The same name covers more than one vial. Pick the one you have — a dose in units written for one of these is wrong for the other.
| Compound | Per vial | Share | Bought separately |
|---|---|---|---|
| GHK-CuLargest component by mass and the source of the blue colour. | 50 mg | 63% | $14–$30 |
| BPC-157Associated with angiogenesis in animal models. | 10 mg | 13% | $18–$50 |
| TB-500Associated with cell migration through actin binding. | 10 mg | 13% | $12–$60 |
| KPVThe addition that distinguishes KLOW from GLOW. Anti-inflammatory in cell and animal work. | 10 mg | 13% | $14–$47 |
| Total | 80 mg | $58–$187 |
The current formulation, and what almost every vendor now ships.
The ratio is fixed in the vial: choosing a dose of one component chooses the dose of all the others. The separate-vials column is the cheapest confirmed listing to the median across vendors, for the masses this vial holds. We do not price blend vials themselves — hold it against whatever you are being quoted.
KLOW takes the GLOW formula and adds KPV, typically producing an 80 mg vial: 50 mg GHK-Cu with 10 mg each of BPC-157, TB-500 and KPV. The stated rationale is that KPV contributes anti-inflammatory activity through a pathway the other three do not touch.
Four compounds at a fixed ratio means four doses chosen at once. The GHK-Cu share is still five times any other component, so the arithmetic problem GLOW has is unchanged. There is simply one more number in it.
This is the least-studied of the common blends, which is a meaningful statement given that none of them has been studied at all as a mixture.
How it works
Four separate mechanisms arriving together, none studied in combination.
GHK-Cu delivers copper for collagen and elastin synthesis.
BPC-157 is associated with angiogenesis in animal models.
TB-500 binds actin and is associated with cell migration.
KPV is a tripeptide fragment of alpha-MSH with anti-inflammatory activity in cell and animal work, particularly in the gut.
What it is studied for
Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.
Tissue repair with an anti-inflammatory component
Published reviewWhat the combination is sold for.
EvidenceNo study of the mixture exists. Every component is separately supported by animal or cell-culture work only.
Regulatory status
Last reviewed 20 Aug 2026. Positions in this category change frequently, so we date the line.
Not approved anywhere as a mixture or as any of its parts. Sold as a research chemical, with ratios that vary between vendors.
Identity and clearance
What the molecule is, and how long a dose stays measurable.
Molecule
- Class
- Pre-mixed blend of four peptides, 5:1:1:1 by mass
An 80 mg vial is 50 mg GHK-Cu with 10 mg each of BPC-157, TB-500 and KPV.
Dose protocols reported in sources
Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.
| Goal | Dose | Frequency | Route | Units, 80 mg vial | Source | Start this protocol |
|---|---|---|---|---|---|---|
| Commonly described community protocol | 2 mg – 4 mg | Daily, in courses of 4 to 8 weeks | SubcutaneousTotal blend. At 5:1:1:1, 2,000 mcg of blend delivers 250 mcg each of BPC-157, TB-500 and KPV alongside 1,250 mcg of GHK-Cu. | 12.5–25 u | Community practice | Start this |
The doses above in syringe units, for the vial you have:
Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.
CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.
Work out what to draw
Pre-filled with a 80 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.
Draw to 12.5 units on a 1 mL U-100 syringe. That is 0.125 mL, containing 2 mg of KLOW.
Check12.5 units falls between the printed lines on a 1 mL U-100 syringe. Mixing with 4.8 mL of water instead would put this dose at 12 units.
BioAlmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.
Open this calculation in the full calculator
Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.
Safety
Reported effects, the situations that need care, and the ones that mean stop.
Reported effects
- Everything from four compounds at oncePublished review
Unknown
No human study of the mixture, and no way to isolate which component caused a reaction.
- Injection site reactionsCommunity practice
Commonly reported
When to stop
- Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
- An injection site that becomes hot, spreading or produces pus.
- Any new lump or unexplained persistent symptom.
Interactions and situations that need care
- Active or previous cancerAvoid
Components associated with angiogenesis and proliferation in animal models, none studied in anyone with a malignancy.
- Wilson's disease or any copper metabolism disorderAvoid
GHK-Cu delivers copper deliberately and is the largest component.
- Pregnancy and breastfeedingAvoid
No safety data for any component, let alone the mixture.
- Wanting to control the dose of one componentUse caution
Four compounds at a fixed ratio means four doses chosen at once. Running them separately is the only way to dose them separately.
- Competing in a tested sportAvoid
Components are WADA S2, prohibited at all times.
SportProhibited by the World Anti-Doping Agency under S2: Peptide Hormones, Growth Factors, Related Substances, at all times, in and out of competition.
What to expect
What the sources describe over time, and how confident anyone can be about it.
HonestlyThere is no human efficacy data for this compound, so there is no evidence-based timeline to give. Any site publishing a week-by-week schedule of expected effects has invented it.
- The least-studied of the common blends, in a category where none has been studied as a mixture.
- Four fixed doses chosen at once. GHK-Cu remains five times any other component.
- KPV is the only difference from GLOW. If you do not want it, GLOW is the same blend without it.
- Ratios differ between vendors.
Storage and combinations
How to keep it, and what it does and does not go with.
Storage and handling
- Freeze-dried powder
- Refrigerated at 2–8 °C, protected from light.
- After mixing
- Refrigerated at 2–8 °C and used within about 30 days. A blend cannot be split. A contaminated vial takes every component with it.
- Long-term, frozen
- Unopened powder is stable at −20 °C or colder.
With other peptides
- GLOWcaution
GLOW is this blend without KPV. Running both means taking the same three compounds twice.
- Klowverinecaution
Klowverine is this blend with BPC-157, TB-500 and KPV each doubled. Running both means taking all four twice.
- Wolverinecaution
Wolverine is two of this blend's four components. Running both means taking BPC-157 and TB-500 twice.
- Deadpoolcaution
Deadpool is three of this blend's four components. Running both means taking BPC-157, TB-500 and KPV twice.
Checking your vial
Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it.
Blue solution after reconstitution
The copper complex, as in GLOW.
Cloudiness or visible particles
Discard it.
No stated ratio
With four components the split matters more, not less.
Vocabulary on this page
- Blend
- One vial containing several peptides at a fixed ratio, reconstituted and drawn together.
- Vial
- The small sealed glass container a peptide is sold in, holding a stated mass of freeze-dried powder under a rubber stopper.
- Stack
- Several separate compounds run at the same time, each in its own vial and on its own schedule.
- Injection site
- Where on the body an injection is given. Rotating between sites is standard practice for anything given repeatedly.
- Protocol
- One compound, with a dose, a frequency and a length: the plan, as opposed to what was actually taken.
Questions
- What does KPV add over GLOW?
- An anti-inflammatory mechanism the other three do not have. KPV is a fragment of alpha-MSH, with activity shown in cell and animal work, particularly in the gut. Whether it adds anything in this mixture has not been examined.
- How much of each am I taking?
- At 5:1:1:1 in an 80 mg vial, five-eighths of any draw is GHK-Cu and one-eighth each is BPC-157, TB-500 and KPV.
References
Everything on this page that came from a source, with the source.
Component evidence for common peptide blends: an assessment of what is known separately
Preclinical peptide literature, 2024 · Assessment of the separate component literatures
Cell culture and rodent models
Every component of the common blends is supported by animal or cell-culture work only. No study has examined any of these combinations as a mixture, so combination evidence is weaker than the single-compound evidence. That is itself preclinical.
Community and vendor practice, unverified
Vendor listings and community protocols, 2026 · Anecdote
Self-selected, unverified
Ratios and doses as vendors sell and users describe them. Ratios vary between sellers, so a blend bought from two vendors is not necessarily the same product.
Related compounds
GLOW
A pre-mixed vial of GHK-Cu, BPC-157 and TB-500 at 5:1:1. One draw delivers all three, in proportions most people underestimate.
Klowverine
A four-peptide blend of 50 mg GHK-Cu with 20 mg each of BPC-157, TB-500 and KPV, which is KLOW with the three repair peptides doubled. The least documented of the named blends.
Wolverine
BPC-157 and TB-500 in one vial at 1:1. The oldest and simplest of the named blends, and the only one without a settled vial size.
Deadpool
Wolverine with KPV added and the ratio tilted toward TB-500: 10 mg TB-500 with 5 mg each of BPC-157 and KPV. Documented at a single vendor.
Next
What to do with KLOW
- Keep a record of itTurn a dose and a schedule into a protocol, then log what you actually take. KLOW is filled in for you.
- See what it costsPer-milligram prices read from vendor sites and confirmed by a person, so vial sizes compare.
- Check a combinationWhat our profiles record about KLOW alongside each other compound — including the pairs where nothing is recorded.
Keep this page honest
If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. No clinician reviews these pages.
Page last updated 20 Aug 2026